AURELIUS Equity Opportunities co-invests in the acquisition of McKesson UK
DGAP-Ad-hoc: AURELIUS Equity Opportunities SE & Co. KGaA / Key word(s): Takeover Inside Information according to Article 17 MAR AURELIUS Equity Opportunities co-invests in the acquisition of McKesson UK The deal with an enterprise value of GBP 477 million will be acquired through the recently launched co-investment structure with AURELIUS European Opportunities Fund IV controlling a 70% stake and AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8) controlling 30%. The transaction is expected to close in Q1 2022, subject to customary closing conditions, including receipt of required regulatory approvals. The McKesson UK business has an established position in the healthcare sector, comprising Lloyds Pharmacy as well as wholesale pharmaceuticals distributor, AAH Pharmaceuticals and generated over GBP 5 billion in revenues and an EBITDA in the high double-digit millions in 2020. McKesson UK operates four divisions: retail, digital, homecare and wholesale. The business has over 18,000 employees, including pharmacists, nurses, logistics operatives as well as store, warehouse and administration personnel. To find out more, visit www.aureliusinvest.com CONTACT
01-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | AURELIUS Equity Opportunities SE & Co. KGaA |
Ludwig-Ganghofer-Straße 6 | |
82031 Grünwald | |
Germany | |
Phone: | +49 (0)89 544 799-0 |
Fax: | +49 (0)89 544 799-55 |
E-mail: | info@aureliusinvest.de |
Internet: | www.aureliusinvest.de |
ISIN: | DE000A0JK2A8 |
WKN: | A0JK2A |
Listed: | Regulated Unofficial Market in Berlin, Frankfurt, Hamburg, Munich (m:access), Stuttgart, Tradegate Exchange |
EQS News ID: | 1245133 |
End of Announcement | DGAP News Service |
|
1245133 01-Nov-2021 CET/CEST